Participated · Series B · Sep 2020

Ionpath develops MIBI (Multiplexed Ion Beam Imaging) technology for high-definition spatial proteomics. Its platform provides highly multiplexed, quantitative protein imaging with sensitivity and true subcellular resolution down to 350 nm. The company sells MIBIscope instruments and offers end-to-end Spatial Proteomics Services to translational and clinical researchers. Customers include pharmaceutical, biotechnology, and research organizations working in immuno-oncology, immunology, neuroscience, and infectious disease research. Ionpath says its technology delivers the throughput and reproducibility required for clinical studies. The company plans to scale its organization to support increasing demand and to accelerate development efforts in collaboration with strategic partners. IONpath develops high-definition spatial proteomics and a multiplexed ion beam imaging (MIBI) platform to enable deeper understanding of the tissue microenvironment. Its technology provides multiplexed, quantitative single-cell analysis for tissue imaging and analysis. The company combines MIBI technology with pathology and data-science expertise to deliver actionable insights to translational and clinical researchers. Target users include pharmaceutical, biotechnology, and research organizations working in immuno-oncology, immunology, neuroscience, and infectious disease research. Led by CEO Sander Gubbens, PhD, IONpath aims to accelerate medical discovery and improve human health. The company planned to use the Series B proceeds to continue expanding operations and its business reach.

Participated · Series B · Aug 2020

Podimetrics developed the FDA-cleared SmartMat™, an easy-to-use at-home mat that detects temperature changes in patients’ feet and alerts the company’s clinical and patient support team. The SmartMat is paired with integrated clinical care services aimed at preventing amputations in complex diabetic patients. Podimetrics partners with regional and national health plans and at-risk providers, including the Veterans Health Administration, to drive adoption. The company reports high patient engagement rates and emphasizes keeping vulnerable populations healthy in their homes. Founded in 2011 and based in Somerville, Mass., and Menlo Park, Calif., Podimetrics plans to expand its commercial operations. It received growth capital to support that expansion. Podimetrics develops the FDA-cleared SmartMat™ and integrated clinical care services aimed at preventing amputations and other complications in complex diabetic patients. The company partners with regional and national health plans and at-risk providers, including the Veterans Health Administration, to deliver its monitoring and care services. Podimetrics plans to use the new funding to hire and build out product development and research teams. It also intends to expand the breadth of services delivered by its nurse support team. The company was founded in 2011 by Jon Bloom, MD, who serves as CEO, and is based in Somerville, Massachusetts. The article does not disclose operating metrics such as revenue or user counts. Podimetrics offers a remote physiologic monitoring solution centered on its FDA-cleared SmartMat, which patients stand on for 20 seconds daily so data are sent to a care management team. The company partners with payers and at-risk providers, including the Veterans Health Administration, and its services are used in more than 40 VA medical facilities. Podimetrics reports more than 300% growth in the first half of 2020 versus the prior year and earns high patient engagement rates. The SmartMat is manufactured in Massachusetts and has the American Podiatric Medical Association Seal of Approval. Podimetrics was founded in 2011 by a physician and engineers from MIT and Harvard and is headquartered in Somerville, MA. With new advisory board additions, the company is expanding its commercial presence to reach more at-risk patients in the VHA and private payer markets. Podimetrics offers a preventive care solution for diabetic foot ulcers consisting of an FDA-cleared, cellular-connected SmartMat paired with a care management team that triages concerning findings. High-risk patients place their feet on the mat for about 20 seconds daily and the device automatically transmits data for review. The company delivers this service on behalf of payers and at-risk providers. Podimetrics closed a $13.4M Series B to fund its growth. Management intends to use the proceeds to accelerate adoption within the Veterans Affairs health care system and among commercial payers nationwide. The company is focused on scaling deployment and payer relationships to expand monitoring and early intervention. Podimetrics builds a bathroom-mat sensor system that scans patients' feet, sends blood-flow data to the cloud, and uses algorithms to analyze longitudinal trends and left-right comparisons to detect pre-ulcers. When the algorithms detect a developing ulcer, the system sends alerts to the patient and their doctor to prompt early intervention. The device takes about 30 seconds to use each day. The company graduated from Rock Health’s healthcare accelerator. Podimetrics says it will use recent investment proceeds to develop additional products to help people with diabetes. Since October the company has raised $2.5 million, per the article.

Participated · Series A · May 2017

ReThink Medical develops a proprietary technology platform that analyzes ambulatory physiologic data and uses predictive algorithms to identify worsening conditions in heart failure patients and alert physicians. The company combines medical devices and digital health software to enable proactive, data-driven intervention to prevent hospitalizations. ReThink was founded in 2010 and is led by CEO Reza Naima. Prior to this financing it had secured two NIH grants and entered a strategic partnership with Terumo Corporation. The company intends to use the new capital to fund clinical trials and further invest in its proprietary platform. The financing and existing grants/partnership position ReThink to advance clinical validation and commercialization efforts.

Participated · Series A · Mar 2016

Arterys is a San Francisco, CA-based global medical imaging platform that delivers clinical AI products over the internet. Led by co-founder and acting CEO John Axerio-Cilies, the company provides a web-based, AI-powered, FDA-cleared cloud-native viewer and platform. It operates a marketplace and ecosystem of partners to develop and deliver clinical applications built on its platform. The company raised $28m in a Series C to broaden that ecosystem and accelerate partner efforts. Arterys plans to extend its proprietary technology to application partners to make it easier for clinicians to integrate AI into their workflows from a single interface. The company emphasizes accelerating partners’ efforts to bring new clinical-grade AI applications to providers through its platform. Arterys is a San Francisco-based provider of a web-based AI platform for medical image analytics that enables physicians to process patient imaging cases with embedded AI algorithms. The cloud platform supports MRI and CT and offers image interpretation, case sharing, and automated reporting. Its proprietary technology protects patient information and complies with U.S. and EU data privacy regulations. Arterys' Cardiac MRI suite was the first product of its kind to obtain FDA clearance for use as a diagnostic support tool and is also cleared in Canada and the EU. The platform and cardiac MRI suite have been used to help diagnose more than 15,000 patients worldwide. The company plans to use the new funding to expand its web-based AI platform, launch oncology and neurology products, and accelerate commercialization of its cardiac offering. Arterys develops deep-learning diagnostic software for medical imaging that connects to standard MRI machines to enable non-invasive, precise quantitation of blood flow. The cloud-based platform uploads 10-minute chest MRI scans to a HIPAA-compliant server for computation and presents results in a web browser for clinician interaction and rapid approval of quantitative analyses. The solution targets cardiovascular applications including structural heart disease, congenital heart disease, carotid/neurovascular and renal vascular disease. The company plans to expand commercial operations for its visualization and quantification algorithm using proceeds from its recent Series A. The platform has regulatory clearances—CE Mark and U.S. FDA market clearance (March 2014)—and is already used for research at leading hospitals in the U.S. and Europe. Arterys anticipates broader distribution through ViosWorks in up to 7,000 GE MRI machines in H2 2016; the company is led by founder and CEO Fabien Beckers.

Participated · Series D · Mar 2015

Daktari Diagnostics is developing the CarePlatform™, an immunoassay-based, highly portable point-of-care device that integrates proprietary detection technology, automated whole-blood sample preparation in a single-use disposable cartridge, and wireless cloud connectivity. The platform is designed to deliver HIV viral load counts from whole blood in under 30 minutes and aims to address diagnostic access gaps in global health settings. Daktari’s viral load test quantifies virion-associated p24 protein rather than free p24, and a preliminary study showed strong correlation with standard RT-PCR viral load values. The company reports the potential to achieve a limit of detection equivalent to 1,000 copies/mL, a clinically relevant threshold defined by WHO. Daktari is collaborating with Partners for Health and Development in Africa (PHDA) and Dr. Julius Oyugi (University of Nairobi) on the project. The work is intended to help reach patients in developing countries who are presently inaccessible to lab-based systems. Daktari Diagnostics develops portable diagnostic instruments that can be deployed in pharmacies, physicians’ offices and remote health facilities worldwide. The company’s first application on its platform, Daktari CD4, completed clinical validation studies in January 2015 and is slated for global commercialization in 2015. Daktari plans to expand its platform with Daktari Virology, which will add molecular tests for HCV and HIV in a non‑PCR format. The company is led by founder and CEO Bill Rodriguez, M.D. Daktari is based in Cambridge, USA. Financially, the company closed a $15.5M Series D in early 2015. Daktari Diagnostics develops simple, accurate, and affordable handheld HIV monitoring devices. The company focuses on delivering critical diagnostic test results to clinicians and patients across the globe. Its team of engineers, scientists, physicians, and global health experts is dedicated to creating high-performance products. Products are specifically designed for resource-poor markets. Daktari raised $7 million in a venture capital round, according to an SEC filing. Twenty-six separate investors participated in the financing. Daktari Diagnostics develops point-of-care diagnostic systems aimed at global health, focusing on simple, accurate, and affordable tests. Its system is designed to analyze small volumes of blood or other fluids for use in any type of health care setting. The company intends to use the financing to complete development and bring to market initial products for monitoring HIV patients worldwide and to expand its point-of-care product development pipeline. The underlying technology was initially developed at Massachusetts General Hospital. Daktari was founded in 2008 and is led by CEO Bill Rodriguez, M.D. The company is based in Cambridge, Mass., is currently hiring, and recently raised $10M in the reported financing. Daktari Diagnostics develops a hand-held point-of-care device that counts CD4 cells to determine immune function in HIV/AIDS patients. The device is designed to provide on-site CD4 counts, avoiding the time-consuming and costly lab-based testing common in many parts of Africa and other developing countries. The company is Cambridge, Mass.-based. Financially, Daktari disclosed an equity financing of $1.8 million in an SEC filing and has previously completed a $2.8 million round in Sept. 2009 and later added $820,000 in June. The SEC filing states the new capital came from 32 unnamed investors and names several directors and the CEO on prior securities documents. Daktari's product aims to enable faster point-of-care assessment of HIV progression by providing CD4 counts without centralized labs.